文献速递精神分裂症与精神病性障碍

精神病脑亚型在首发队列中得到验证并与疾病缓解相关:PHENOM联盟结果

Psychosis brain subtypes validated in first-episode cohorts and related to illness remission: results from the PHENOM consortium.
PubMed 文献 · Mol Psychiatry · 2023-05-05

基于PHENOM联盟4个中心572例首发精神病(FEP)和424名健康对照(HC),应用先前基于671名参与者训练的MRI亚组分类模型,发现SG1(低脑容积)和SG2(高纹状体容积)两种神经解剖亚型在首发时已存在,且与不同临床表现及1年、5年缓解相关。

要点

  • SG1在FEP中占比(32%)显著高于HC(19%),SG2在FEP(21%)与HC(23%)间无显著差异。
  • SG1与SG2的临床多变量特征可区分(平衡准确率64%,p<0.0001)。
  • SG2表现为更高教育水平但首发阳性症状更重,且与1年、5年及合并时间点的症状缓解相关。

核心结论

  • 精神分裂症的神经形态学亚型在疾病发作时即已显现,并具有不同的临床表现和后续缓解关联。

研究设计与样本

  • 研究纳入PHENOM联盟4个中心(圣保罗、桑坦德、伦敦、墨尔本)的572例FEP和424名HC。
  • 将先前基于671名参与者(美国、德国、中国)的MRI亚组分类模型应用于FEP和HC,分为SG1、SG2、无亚组归属和混合亚组四类。

主要发现

  • SG1(低脑容积)在FEP中占比32%,显著高于HC的19%;SG2(高纹状体容积)在FEP中占比21%,HC为23%。
  • 临床多变量特征可区分SG1和SG2(平衡准确率64%,p<0.0001)。
  • SG2与更高教育水平、首发时更严重的阳性精神病症状相关,并与1年、5年及合并时间点的症状缓解相关。

关键数值与推荐

  • SG1在FEP中占比32%,HC为19%;SG2在FEP中占比21%,HC为23%。
  • SG1与SG2的临床多变量特征区分平衡准确率为64%(p<0.0001)。

临床怎么用

  • 提示神经解剖亚型可在首发精神病时识别,未来治疗试验可考虑针对这些亚型。
  • 解读神经影像文献时需考虑亚型异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Using machine learning, we recently decomposed the neuroanatomical heterogeneity of established schizophrenia to discover two volumetric subgroups-a 'lower brain volume' subgroup (SG1) and an 'higher striatal volume' subgroup (SG2) with otherwise normal brain structure. In this study, we investigated whether the MRI signatures of these subgroups were also already present at the time of the first-episode of psychosis (FEP) and whether they were related to clinical presentation and clinical remission over 1-, 3-, and 5-years. We included 572 FEP and 424 healthy controls (HC) from 4 sites (Sao Paulo, Santander, London, Melbourne) of the PHENOM consortium. Our prior MRI subgrouping models (671 participants; USA, Germany, and China) were applied to both FEP and HC. Participants were assigned into 1 of 4 categories: subgroup 1 (SG1), subgroup 2 (SG2), no subgroup membership ('None'), and mixed SG1 + SG2 subgroups ('Mixed'). Voxel-wise analyses characterized SG1 and SG2 subgroups. Supervised machine learning analyses characterized baseline and remission signatures related to SG1 and SG2 membership. The two dominant patterns of 'lower brain volume' in SG1 and 'higher striatal volume' (with otherwise normal neuromorphology) in SG2 were identified already at the first episode of psychosis. SG1 had a significantly higher proportion of FEP (32%) vs. HC (19%) than SG2 (FEP, 21%; HC, 23%). Clinical multivariate signatures separated the SG1 and SG2 subgroups (balanced accuracy = 64%; p < 0.0001), with SG2 showing higher education but also greater positive psychosis symptoms at first presentation, and an association with symptom remission at 1-year, 5-year, and when timepoints were combined. Neuromorphological subtypes of schizophrenia are already evident at illness onset, separated by distinct clinical presentations, and differentially associated with subsequent remission. These results suggest that the subgroups may be underlying risk phenotypes that could be targeted in future treatment trials and are critical to consider when interpreting neuroimaging literature.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Dwyer DB, Chand GB, Pigoni A, et al. Psychosis brain subtypes validated in first-episode cohorts and related to illness remission: results from the PHENOM consortium. Mol Psychiatry. 2023. PMID: 37147389. doi:10.1038/s41380-023-02069-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。